Welcome to our dedicated page for Fibrobiologics SEC filings (Ticker: FBLG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company based in Houston that develops fibroblast-based therapies and fibroblast-derived materials for chronic diseases. These regulatory documents offer detailed information on the company’s capital structure, governance, financing arrangements, and stockholder proposals.
FibroBiologics’ filings include Forms 8-K describing material events such as securities purchase agreements, registered direct offerings, concurrent private placement warrants, use of sovereign-issued gold coins as consideration in one offering, and the payoff of convertible promissory notes issued under a Standby Equity Purchase Agreement. Other 8-K filings disclose Nasdaq notices related to minimum bid price and Market Value of Listed Securities requirements, along with the company’s potential options to address these listing standards.
The company’s proxy statements on Schedule 14A outline items submitted to stockholders, including a proposed reverse stock split within a specified ratio range, approvals for issuances of common stock underlying various warrant agreements under Nasdaq Listing Rule 5635(d), and an adjournment proposal. These documents also discuss voting rights, such as the Series C Preferred Stock with super voting rights and the irrevocable proxy in favor of the board of directors.
Through this page, users can review FibroBiologics’ annual and quarterly reports when available, current reports on Form 8-K, and proxy materials, with AI-powered tools that summarize key terms, highlight financing structures, and clarify complex provisions. Investors can also use the filings to understand warrant terms, reverse split authorizations, Nasdaq compliance disclosures, and other regulatory details that shape the risk and capital profile of FBLG.
FibroBiologics, Inc. is soliciting votes at its virtual Annual Meeting on June 22, 2026 on director elections, auditor ratification, Nasdaq approval for certain March 2026 warrant issuances, and adoption of a new 2026 Equity and Incentive Compensation Plan. The board recommends FOR on all proposals and discloses that 125 shares of Series C Preferred Stock (held by the CEO) carry super‑voting rights totaling 1,625,000 votes the board will cast via an irrevocable proxy. The proxy materials state there were 5,208,915 shares of common stock outstanding as of April 24, 2026. The March Offering included warrants that could convert into up to 2,272,728 shares (exercise price $1.32) and placement agent warrants for up to 159,091 shares (exercise price $1.65), for which shareholder approval under Nasdaq Rule 5635(d) is being requested.
FibroBiologics, Inc. has received formal confirmation from Nasdaq that it now meets all requirements for continued listing on The Nasdaq Capital Market. Nasdaq verified compliance with both the $2.5 million stockholders’ equity requirement and the $1.00 bid price requirement, closing the previously disclosed listing matter.
The company’s common stock will continue trading under the symbol FBLG, but Nasdaq will apply one-year Mandatory Panel Monitor periods for both equity and bid price tests. If FibroBiologics falls out of compliance during these periods, Nasdaq staff would move directly to a delisting determination, though the company could request a new hearing to temporarily stay any delisting action.
FibroBiologics, Inc. reports that its board of directors approved an amendment and restatement of the company’s Bylaws on April 16, 2026. The change revises Section 2.07 to lower the quorum requirement for stockholder meetings from a majority of the voting power to one-third of the voting power.
The revised section keeps existing provisions that allow the meeting chair or stockholders present to adjourn meetings if a quorum is not reached and confirms that once a quorum is established, it is not lost by subsequent withdrawal of votes. The company filed its Second Amended and Restated Bylaws as an exhibit.
FibroBiologics, Inc. filed an amended current report to correct an omitted item number, without changing any prior disclosures. The company highlights a Sublease Buyout Agreement that ended its Webster, Texas sublease effective April 2, 2026, ahead of the original November 30, 2027 expiration.
FibroBiologics resolved all remaining rent obligations with a single payment of $45,108.25 and expects to save approximately $0.8 million in future rent. This move follows the 2025 opening of a new laboratory facility with over 10,000 square feet of lab and office space and supports consolidating operations. The company also updates its principal executive office address to 9350 Kirby Drive, Suite 300, Houston, Texas 77054.
FibroBiologics, Inc. Schedule 13G shows Lind Global Fund III LP and related reporting persons beneficially own 230,234 shares, representing 4.99% of common stock. The filing explains the position reflects 157,956 shares plus 540,536 warrants whose conversion is contractually limited to avoid ownership above 4.99%.
FibroBiologics, Inc. terminated its sublease for office space in Webster, Texas through a Sublease Buyout Agreement effective April 2, 2026, well before the original November 30, 2027 end date. The company made a single payment of $45,108.25 and expects to save approximately $0.8 million in future rent.
The change follows FibroBiologics’ 2025 opening of a new state-of-the-art laboratory facility with over 10,000 square feet of lab and office space and supports its consolidation of operations. The company’s principal executive offices are now located at 9350 Kirby Drive, Suite 300, Houston, Texas 77054.
FibroBiologics, Inc. approved a capital change by implementing a one-for-twenty reverse stock split of its common stock. The Certificate of Amendment became effective at 12:01 a.m. Eastern Time on March 30, 2026, converting every 20 issued and outstanding common shares into 1 share.
No fractional shares will be issued; any fractional share will be rounded up to the nearest whole share. The reverse split proportionately adjusts shares available under the equity incentive plan and existing options and warrants, but does not change the common stock’s par value, authorized share count, or the Nasdaq trading symbol FBLG.
FibroBiologics, Inc. completed a best-efforts public offering of 2,272,728 shares of common stock or equivalents and accompanying warrants, raising approximately $3 million in gross proceeds at a combined price of $1.32 per share and warrant. Net proceeds were about $2.5 million after fees, and are earmarked for working capital and general corporate purposes.
Investors also received warrants to purchase up to 2,272,728 additional shares at $1.32 per share, exercisable only after stockholder approval and expiring five years after that approval. If fully exercised for cash, these warrants could provide roughly $3 million in additional gross proceeds. Pre-funded warrants, issued at $1.31999 with a $0.00001 exercise price, are immediately exercisable and do not expire, subject to 9.99% beneficial ownership limits, while the other warrants and placement agent warrants carry a 4.99% ownership cap.
FibroBiologics is offering 1,028,788 shares of common stock, 1,243,940 pre-funded warrants and accompanying warrants to purchase up to 2,272,728 shares, at a combined public offering price of $1.32 per share plus warrant. Each public Warrant has an exercise price of $1.32 and is exercisable only after the effective date of the Warrant Stockholder Approval. Pre-Funded Warrants are exercisable for $0.00001 per share and are issued to limit single‑holder ownership above 4.99% (or electively 9.99%). The offering contemplates Placement Agent compensation including 159,091 Placement Agent Warrants and assumes delivery in a single closing. The prospectus gives effect to a 1-for-20 reverse stock split effective March 30, 2026, and states estimated net proceeds of approximately $2.5 million assuming full cash exercise of the Pre-Funded Warrants. The company remains listed on Nasdaq under FBLG and is taking these actions while seeking to regain compliance with Nasdaq bid-price requirements.
FibroBiologics, Inc. is registering up to 1,136,363 shares of common stock, up to 1,136,363 pre-funded warrants and related warrants in a best efforts public offering. Each share or pre-funded warrant is sold with a warrant, at an assumed combined price of $4.40. The company estimates net proceeds of about $4.3 million, intended for working capital and general corporate purposes. A 1-for-20 reverse stock split effective March 30, 2026 will reduce outstanding common shares from 70,256,883 to approximately 3,512,845, mainly to help regain Nasdaq bid-price compliance. The offering has no minimum size, may close with reduced proceeds and will cause immediate dilution for new investors.